CXCL12 and neoplasm: The CAFs, recruited to the tumor site by TGF-beta and CXCR4/CXCL12 signaling, enhance cancer cell proliferation and polarize adaptive and innate immune cells toward a tumor-promoting phenotype (also conferring immunotherapy resistance) (86).